Joint initiative integrates submitted claims with parties’ platforms in effort to avoid duplicate data.
IntegriChain, a data and managed services company, and Second Sight Solutions, a health technology business that offers pharma manufacturers a solution to transparency and compliance in the 340B program, are collaborating on a new joint initiative surrounding 340B drug pricing program duplicate discount prevention.
The initiative, when implemented in Q3 of this year, will be capable of integrating 340B claims submitted by covered entities and contract pharmacies to Second Sight’s branded 340B ESP platform into IntegriChain’s ICyte script management solution, which retrieves, validates, and reconciles all claims at scale.
“340B contract pharmacy arrangements have grown at an annual rate exceeding 25% over the past five years,” comments Second Sight Director Andrew Brownlee. “Pharmaceutical manufacturers have noted that these purchases present a risk of program non-compliance and are utilizing the 340B ESP platform to respond through policies that address program integrity. We believe this initiative with IntegriChain will help serve the industry by streamlining the removal of ineligible rebates identified by the 340B ESP platform.”